Price T Rowe Associates Inc Supernus Pharmaceuticals, Inc. Transaction History

Price T Rowe Associates Inc

$836 Billion
Q2 2024

A detailed history of Price T Rowe Associates Inc transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 47,523 shares of SUPN stock, worth $1.79 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

47,523

Previous 442,757 89.27%

Holding current value

$1.79 Million

Previous $15.1 Million 91.58%

% of portfolio

0.0%

Previous 0.0%

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$25.99 - $33.85 $10.3 Million - $13.4 Million	-395,234 Reduced 89.27%	47,523 $1.27 Million
Q1 2024 May 15, 2024	SELL	$27.11 - $35.17 $69,374 - $90,000	-2,559 Reduced 0.57%	442,757 $15.1 Million
Q4 2023 Feb 14, 2024	SELL	$22.72 - $29.68 $728,494 - $951,659	-32,064 Reduced 6.72%	445,316 $12.9 Million
Q3 2023 Nov 14, 2023	SELL	$27.57 - $32.91 $982,153 - $1.17 Million	-35,624 Reduced 6.94%	477,380 $13.2 Million
Q2 2023 Aug 14, 2023	BUY	$29.91 - $38.73 $90,687 - $117,429	3,032 Added 0.59%	513,004 $15.4 Million
Q1 2023 May 15, 2023	BUY	$34.93 - $42.03 $21,621 - $26,016	619 Added 0.12%	509,972 $18.5 Million
Q4 2022 Feb 14, 2023	BUY	$31.09 - $37.88 $46,324 - $56,441	1,490 Added 0.29%	509,353 $18.2 Million
Q3 2022 Nov 14, 2022	SELL	$28.79 - $35.41 $25,479 - $31,337	-885 Reduced 0.17%	507,863 $17.2 Million
Q2 2022 Aug 15, 2022	SELL	$25.33 - $34.25 $189,443 - $256,155	-7,479 Reduced 1.45%	508,748 $14.7 Million
Q1 2022 May 16, 2022	SELL	$28.51 - $32.9 $19,785 - $22,832	-694 Reduced 0.13%	516,227 $16.7 Million
Q4 2021 Feb 14, 2022	SELL	$26.37 - $34.22 $139,998 - $181,673	-5,309 Reduced 1.02%	516,921 $15.1 Million
Q3 2021 Nov 15, 2021	SELL	$23.54 - $31.39 $2 Million - $2.67 Million	-85,163 Reduced 14.02%	522,230 $13.9 Million
Q2 2021 Aug 16, 2021	SELL	$26.72 - $33.19 $26,452 - $32,858	-990 Reduced 0.16%	607,393 $18.7 Million
Q1 2021 May 17, 2021	SELL	$24.15 - $31.45 $642,245 - $836,381	-26,594 Reduced 4.19%	608,383 $15.9 Million
Q4 2020 Feb 16, 2021	BUY	$17.7 - $25.81 $11.2 Million - $16.4 Million	634,977 New	634,977 $16 Million

Others Institutions Holding SUPN

# of Institutions

264

Shares Held

59.4M

Call Options Held

47.9K

Put Options Held

13.1K

View Full List

About SUPERNUS PHARMACEUTICALS, INC.

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $2.02B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

More about SUPN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.

Account

Price T Rowe Associates Inc Supernus Pharmaceuticals, Inc. Transaction History